WO2024218571 - METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING EOSINOPHILIC ESOPHAGITIS

National phase entry:
Publication Number WO/2024/218571
Publication Date 24.10.2024
International Application No. PCT/IB2024/000197
International Filing Date 18.04.2024
Title **
[English] METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING EOSINOPHILIC ESOPHAGITIS
[French] MÉTHODES ET COMPOSITIONS POUR PRÉVENIR OU TRAITER L'OESOPHAGITE À ÉOSINOPHILES
Applicants **
REVOLO BIOTHERAPEUTICS LIMITED
Inventors
FOULKES, Roly
DE ALBA, Jorge
Priority Data
63/496,921   18.04.2023   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting2427
EPO Filing, Examination, Granting12453
Japan Filing, Examination, Granting2370
South Korea Filing, Examination, Granting2506
USA Filing, Examination, Granting5140
MasterCard Visa
Total: 24,896

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] Described herein are methods for preventing or treating eosinophilic esophagitis (EoE) by administrating peptides related to Chaperonin 60.1 to subjects afflicted with EoE.[French] L'invention concerne des méthodes de prévention ou de traitement de l'oesophagite à éosinophiles (EoE) par administration de peptides associés à la chaperonine 60.1 à des sujets atteints d'EoE.